Key regions: France, Europe, United Kingdom, Brazil, India
The global Oncology Drugs market has been growing rapidly over the past few years due to the increasing prevalence of cancer worldwide. Moldova, a small country in Eastern Europe, has also witnessed a significant growth in the Oncology Drugs market.
Customer preferences: Customers in Moldova prefer generic drugs over branded drugs due to their affordability. This trend is not unique to Moldova but is seen in many developing countries. As Oncology Drugs are expensive, customers tend to opt for generic drugs as they are more affordable.
Trends in the market: The Oncology Drugs market in Moldova has been witnessing a shift towards targeted therapies. Targeted therapies are drugs that target specific proteins or genes that are involved in the growth and spread of cancer cells. These therapies are more effective than traditional chemotherapy as they only target cancer cells and spare healthy cells. The trend towards targeted therapies is seen not only in Moldova but worldwide.
Local special circumstances: Moldova is a small country with a population of around 2.6 million. The country has a high incidence of cancer, with lung and breast cancer being the most common types. The country also has a high mortality rate from cancer. This has led to an increased demand for Oncology Drugs in the country.
Underlying macroeconomic factors: Moldova is a developing country with a low GDP per capita. The country has a weak healthcare system and limited resources. The government has been working towards improving the healthcare system, but progress has been slow. This has led to a lack of access to Oncology Drugs for many patients. The high cost of Oncology Drugs is also a barrier for many patients.In conclusion, the Oncology Drugs market in Moldova is growing due to the high incidence of cancer in the country. Customers prefer generic drugs over branded drugs due to affordability. The trend towards targeted therapies is also seen in Moldova. However, the weak healthcare system and limited resources in the country are a barrier to access to Oncology Drugs for many patients.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
